Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva is based in Lund, Sweden.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Medicon Village, Lund,223 81,sweden
- Phone
- +46 (0)46-275 62 20
- in****@****iva.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- abliva.com
- Keywords
- Mitochondrial medicine, Mitochondrial disorders, primary mitochondrial diseases, MELAS, Leigh.
- HQ
- Lund
Abliva Ab Questions
Abliva Ab's helpline number is +46 (0)46-275 62 20
Abliva Ab's website is abliva.com
Abliva Ab's LinkedIn profile is https://se.linkedin.com/company/abliva
Abliva Ab has
9 employees.
View email and phone details for 9
employees at Abliva Ab.
Abliva Ab's industry is
Pharmaceutical Manufacturing
Abliva Ab's top competitors are
Acucort Ab,
Alligator Bioscience Ab,
Hadean Ventures,
Owl Therapeutics,
Cellevate Ab,
Pharming Group,
Ascelia Pharma Ab,
Active Biotech Ab,
Pila Pharma,
Gryphon Bio.
Abliva Ab's support email address is info@abliva.com
Abliva Ab's categories are Pharmaceutical Manufacturing
Abliva Ab's founding year is 2000
